| Phase 12 trials |
|
Phase 1
|
NCT04728334 |
Mar 2021 → Jan 2022 |
cancer |
Akeso |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04349969 |
Apr 2020 → Nov 2022 |
cancer |
Akeso Biopharma, Inc. |
Completed
|
No outcome recorded
|
| Phase 1/27 trials |
|
Phase 1/2
|
NCT06642792 |
Jan 2025 → Nov 2027 expected |
classic Hodgkin lymphoma |
Akeso |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06387420 |
Apr 2024 → Apr 2026 overdue |
acute myeloid leukemia |
Akeso |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05229497 |
May 2022 → Dec 2026 expected |
cancer |
Akeso |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05235542 |
Mar 2022 → May 2026 |
cancer |
Akeso |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT05214482 |
Jan 2022 → Nov 2025 |
cancer |
Akeso |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT04980885 |
Aug 2021 → Sep 2025 overdue |
acute myeloid leukemia |
Akeso |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT04900350 |
Jun 2021 → Sep 2025 overdue |
myelodysplastic syndrome |
Akeso |
Active not recruiting
|
No outcome recorded
|
| Phase 27 trials |
|
Phase 2
|
NCT07245446 |
Oct 2025 → Dec 2027 expected |
small cell lung carcinoma |
Akeso |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06789848 |
Feb 2025 → May 2029 expected |
biliary tract cancer, hepatocellular carcinoma |
University of Texas Southwestern Medical Center |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06508606 |
Aug 2024 → Aug 2026 overdue |
head and neck squamous cell carcinoma |
West China Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06196203 |
Feb 2024 → Jan 2026 overdue |
myelodysplastic syndrome |
Akeso |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05960955 |
Nov 2023 → Nov 2024 overdue |
gastroesophageal adenocarcinoma |
Akeso |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05382442 |
Jun 2022 → May 2026 overdue |
colorectal cancer |
Akeso |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05227664 |
Mar 2022 → Dec 2026 expected |
triple-negative breast carcinoma |
Akeso |
Active not recruiting
|
No outcome recorded
|
| Phase 33 trials |
|
Phase 3
|
NCT07264075 |
May 2026 → May 2030 expected |
head and neck squamous cell carcinoma |
Groupe Oncologie Radiotherapie Tete et Cou |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06953999 |
Jun 2025 → May 2027 expected |
malignant pancreatic neoplasm |
Akeso |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06601335 |
Oct 2024 → Jan 2027 expected |
head and neck squamous cell carcinoma |
Akeso |
Recruiting
|
No outcome recorded
|